Lionco Pharmaceutical Group Co.,Ltd. (603669.SS)
CNY 6.69
(-3.04%)
CNY 6.69
(-3.04%)
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2023 | -151.49 Million CNY | 22.61% |
| 2022 | -195.74 Million CNY | -397.02% |
| 2021 | 65.9 Million CNY | -58.83% |
| 2020 | 160.07 Million CNY | -20.6% |
| 2019 | 201.59 Million CNY | 10.34% |
| 2018 | 182.7 Million CNY | 13.48% |
| 2017 | 161 Million CNY | 4.6% |
| 2016 | 153.92 Million CNY | 2.83% |
| 2015 | 149.69 Million CNY | -0.11% |
| 2014 | 149.85 Million CNY | 30.54% |
| 2013 | 114.79 Million CNY | 20.62% |
| 2012 | 95.17 Million CNY | 70.7% |
| 2011 | 55.75 Million CNY | 0.0% |
| Year | Net Income | Net Income Growth |
|---|---|---|
| 2024 Q2 | -24.35 Million CNY | -51.85% |
| 2024 Q1 | -16.04 Million CNY | 70.79% |
| 2024 Q3 | -6.48 Million CNY | 73.36% |
| 2023 Q1 | -22.99 Million CNY | 81.79% |
| 2023 FY | -151.49 Million CNY | 22.61% |
| 2023 Q4 | -54.91 Million CNY | -104.43% |
| 2023 Q3 | -26.86 Million CNY | 42.52% |
| 2023 Q2 | -46.72 Million CNY | -103.25% |
| 2022 Q4 | -126.27 Million CNY | -19.85% |
| 2022 Q3 | -105.35 Million CNY | -787.46% |
| 2022 Q2 | 15.32 Million CNY | -25.46% |
| 2022 Q1 | 20.55 Million CNY | 258.39% |
| 2022 FY | -195.74 Million CNY | -397.02% |
| 2021 Q1 | 35.1 Million CNY | 355.14% |
| 2021 Q4 | -12.98 Million CNY | -228.5% |
| 2021 Q3 | 10.1 Million CNY | -70.0% |
| 2021 Q2 | 33.67 Million CNY | -4.08% |
| 2021 FY | 65.9 Million CNY | -58.83% |
| 2020 Q3 | 76.06 Million CNY | 639.82% |
| 2020 FY | 160.07 Million CNY | -20.6% |
| 2020 Q2 | 10.28 Million CNY | -84.42% |
| 2020 Q1 | 66.01 Million CNY | 29.75% |
| 2020 Q4 | 7.71 Million CNY | -89.86% |
| 2019 Q4 | 50.87 Million CNY | 23.44% |
| 2019 Q2 | 73.35 Million CNY | 102.98% |
| 2019 Q1 | 36.14 Million CNY | 118.17% |
| 2019 Q3 | 41.21 Million CNY | -43.81% |
| 2019 FY | 201.59 Million CNY | 10.34% |
| 2018 Q4 | 16.56 Million CNY | -82.92% |
| 2018 FY | 182.7 Million CNY | 13.48% |
| 2018 Q3 | 96.97 Million CNY | 165.56% |
| 2018 Q2 | 36.51 Million CNY | 11.86% |
| 2018 Q1 | 32.64 Million CNY | -49.18% |
| 2017 Q1 | 28.25 Million CNY | -46.28% |
| 2017 Q2 | 30.71 Million CNY | 8.7% |
| 2017 Q3 | 37.8 Million CNY | 23.09% |
| 2017 Q4 | 64.23 Million CNY | 69.92% |
| 2017 FY | 161 Million CNY | 4.6% |
| 2016 Q1 | 26.33 Million CNY | -46.99% |
| 2016 FY | 153.92 Million CNY | 2.83% |
| 2016 Q2 | 46.89 Million CNY | 78.06% |
| 2016 Q3 | 28.1 Million CNY | -40.07% |
| 2016 Q4 | 52.59 Million CNY | 87.17% |
| 2015 Q4 | 49.68 Million CNY | 73.53% |
| 2015 Q3 | 28.63 Million CNY | -34.33% |
| 2015 Q2 | 43.59 Million CNY | 56.92% |
| 2015 Q1 | 27.78 Million CNY | -49.69% |
| 2015 FY | 149.69 Million CNY | -0.11% |
| 2014 Q2 | 43.83 Million CNY | 59.63% |
| 2014 FY | 149.85 Million CNY | 30.54% |
| 2014 Q4 | 55.22 Million CNY | 136.58% |
| 2014 Q1 | 27.46 Million CNY | 0.0% |
| 2014 Q3 | 23.34 Million CNY | -46.75% |
| 2013 FY | 114.79 Million CNY | 20.62% |
| 2012 FY | 95.17 Million CNY | 70.7% |
| 2011 FY | 55.75 Million CNY | 0.0% |